- Home
- SPAI vs MAIA Comparison
SPAI vs MAIA Comparison
Compare SPAI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPAI | MAIA |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 79.0M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | SPAI | MAIA |
|---|---|---|
| Price | $4.42 | $1.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 281.7K | ★ 1.0M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,060.58 | N/A |
| Revenue Next Year | $162.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.47 | $0.87 |
| 52 Week High | $9.16 | $3.19 |
Technical Indicators
Market Signals| Indicator | SPAI | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 54.69 |
| Support Level | $3.66 | $1.38 |
| Resistance Level | $4.74 | $1.50 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 6.81 | 45.16 |
Price Performance
Historical ComparisonAbout SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.